LONDON--Drug development company Synairgen PLC (SNG.LN) said Wednesday that AstraZeneca PLC (AZN.LN) has decided to stop the clinical trial of asthma treatment drug AZD9412, or inhaled interferon beta-1a.

The company said Astra halted the trial because of difficulty in determining primary endpoint as there were very low number of severe exacerbations overall. AstraZeneca will now review the data and study design before deciding on the best way forward for the program, the company added.

The AZD9412 program was developed by Synairgen and licensed to Astra in June 2014.

Shares of Synairgen at 0745 GMT trading 33.8% lower at 23 pence.

Write to Tapan Panchal at tapan.panchal@wsj.com

(END) Dow Jones Newswires

October 12, 2016 04:02 ET (08:02 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Synairgen (LSE:SNG)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Synairgen Charts.
Synairgen (LSE:SNG)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Synairgen Charts.